Max Reinhardt
Known title: President, Rest of WorldCIK: 0001780058
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Viatris agrees to acquire Pacira BioSciences for $1.65 billion. Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.
Transaction History
| OFIX | ▼ Sell | Open Market | 1,053 | $13K | 3/5/2026 | View on chart |
| OFIX | ▼ Sell | Open Market | 1,080 | $14K | 3/4/2026 | View on chart |
| OFIX | ▼ Sell | Open Market | 1,643 | $19K | 6/11/2025 | View on chart |
| OFIX | ▲ Buy | Grant | 14,723 | $0 | 3/3/2025 | View on chart |
| OFIX | ▲ Buy | Grant | 14,401 | $188K | 6/10/2024 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,099 | $42K | 6/7/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,054 | $41K | 6/6/2023 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,380 | $80K | 10/7/2022 | View on chart |
| PCRX | ▲ Buy | Grant | 7,950 | $0 | 6/8/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 2,433 | $151K | 6/7/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 2,817 | $173K | 6/6/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 12,500 | $532K | 4/21/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 9,824 | $720K | 4/21/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 12,500 | $532K | 4/20/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 9,764 | $722K | 4/20/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 12,500 | $532K | 4/19/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 9,321 | $673K | 4/19/2022 | View on chart |
| PCRX | ▲ Buy | Option Exercise | 12,500 | $532K | 4/18/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 8,941 | $658K | 4/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Orthofix pays $24M in damages to former executives
Orthofix Medical has paid $24 million in damages to former executives. This significant cash outflow may impact the company's financial position. The stock currently trades near its 52-week low, with analysts averaging a $13 target price.
Orthofix pays $24M in damages to former executives. Orthofix Medical has paid $24 million in damages to former executives. This significant cash outflow may impact the company's financial position. The stock currently trades near its 52-week low, with analysts averaging a $13 target price.